← NewsAll
United Kingdom news is currently paused for latest updates. We'll resume retrieval when enough requests come in.
kidneyintelX.dkd completes three clinical integrations with US kidney clinics
Summary
Renalytix announced that its kidneyintelX.dkd test completed clinical integrations at three US kidney care practices during the last quarter of 2025, and initial testing volumes have started at all sites.
Content
Renalytix announced that its kidneyintelX.dkd prognostic test completed three clinical integrations with US kidney care providers in the last quarter of 2025. The integrations were implemented directly by the company and initial testing volumes have now commenced at each site. The company is expanding electronic health record integrated testing with one-click ordering and continues a collaboration with Tempus to advance EHR-integrated testing and data collection. Renalytix also noted ongoing corporate engagement at industry events and plans additional integrations in early 2026.
What the company reported:
- The integrations were completed with Joseph P. Addabbo Family Health Center (New York), Central Florida Kidney Specialists (Florida) and The Kidney Experts PLLC (Tennessee).
- Initial testing volumes have commenced across all three integrated sites and one-click ordering was implemented for physician use.
- Renalytix is working with Tempus to advance electronic health record integrated testing and data collection with major US healthcare providers.
- The company described kidneyintelX.dkd as the only FDA-approved and Medicare reimbursed prognostic test for early-stage kidney disease risk assessment and noted Medicare reimbursement at $950 per reportable result.
- The test has been used in over 15,000 patients, producing real-world performance data and reported increases in diagnosis, prognosis, and treatment rates where deployed.
- Renalytix said it expects to complete additional clinical integrations with healthcare providers in early calendar year 2026.
Summary:
The company presents these integrations as part of a measured expansion of its clinical footprint to enable kidneyintelX.dkd testing within existing clinical workflows. Renalytix reports ongoing collaboration with Tempus and says it will update investors on progress and trading in February 2026.
